Rising prevalence of migraine, intense pipeline activity, enhanced use of novel drug classes, rising consumption of unhealthy food, and high-pressure lifestyle are key factors contributing to a high CAGR of migraine drugs market during the forecast period.
Market Size – USD 1.29 Billion in 2018, Market Growth – CAGR of 13.3%, Market Trends– Launch of calcitonin gene-related peptide therapies and increasing acceptance of novel drugs
The Global Migraine Drugs Market was valued at USD 1.29 billion in 2018 and is expected to reach USD 3.51 billion by the year 2026, at a CAGR of 13.3%. Migraine treatments are intended to stop the symptoms or for preventing future attacks on the patients. The factors driving the growth of the target market include the increasing awareness about novel drug classes and the rising incidence of migraines problems across the globe. Also, the launch of calcitonin gene-related peptide (CGRP) is expected to drive the growth of this industry. Migraine is defined as a type of intense and recurring headache accompanied by phonophobia, photophobia, and nausea. The condition arises due to genetic origins. However, emotional imbalances such as depression, stress, anxiety, shock, and excitement can trigger migraine attacks.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2515
There have been various types of medication alternatives for preventing and healing migraines but has severe side effects as well, ranging from weight changes, dizziness, nausea and more in an adult with no background of any other medical condition. For women in pregnancy, sumatriptan are the safest option for the treatment and anticonvulsant medicines are contraindicated. However, the approval of the U.S. Food and Drug Administration for the new class of drug specially designed to treat migraine has transformed the market positively. The new FDA approved drugs are Aimovig (Erenumab), Emgality and Ajovy. In September 2018, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for Emgality (galcanezumab-gnlm), a 120 mg injection for the preventive treatment of migraine in adults.
North America dominates the market in terms of geography. Migraine affects around 36 million Americans or approximately 12% of the population of the region, according to the American Migraine Association. The rising vendor focus on emerging markets such as Asia-Pacific, Latin America and Middle East Africa is predicted to fuel the market growth. Asia-Pacific is projected to see major growth in the future due to increased demand for better healthcare services and strengthened healthcare infrastructure.
Furthermore, increased awareness initiatives, availability of research funds from private as well as public bodies, improvement in the reimbursement scenario for associated medications, and rising awareness about the effectiveness of such medications are among the key factors propelling the growth of Migraine Drugs market.
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2515
Further key findings from the report suggest
To know more about the report @ https://www.reportsanddata.com/report-detail/migraine-drugs-market
For the purpose of this report, Reports and Data has segmented the Migraine Drugs market on the basis of product, route of administration, distribution channel and region:
Product Outlook (Revenue in Million USD; 2016–2026)
Route of Administration Outlook (Revenue in Million USD; 2016–2026)
Distribution Channel Outlook (Revenue in Million USD; 2016–2026)
Regional Outlook (Revenue in Million USD; 2016–2026)
Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2515
Some Highlights of the Report:
Thank you for reading our report. To receive further information on the report or to enquire about its customization, please get in touch with us and get your report tailored according to your needs.
Browse More Related Reports:
Head of Business Development
Direct Line: +1-212-710-1370
Reports and Data | Web:www.reportsanddata.com